Shares of Aperam plunged as much as 9.4% to €43.34 on July 30 after the Luxembourg-based stainless steel producer released Q2 2026 results that, on paper, looked like a milestone. The company called it its "best quarter in four years," reporting adjusted EBITDA of €159 million (€130 million on an adjusted basis), up 44% from Q1's €90 million.
That adjusted figure of €130 million essentially matched the analyst consensus of €129 million — meaning the beat was negligible. The sell-off, amplified by a 1.57% decline in the broader materials sector, signals that investors had already priced in the recovery and were hunting for something more.
• The "Best Quarter" Barely Beat Expectations — The pre-earnings consensus stood at €121 million , but by the time the report landed, the bar had crept up to €129 million. Matching a recently raised consensus in a cyclical business often triggers selling by traders who bought ahead of the good news. The stock had rallied roughly 18% from its April lows near €41.50 into the high €49s last week, leaving little upside surprise for longs.
• The Forward Outlook Took the Air Out — Aperam guided Q3 adjusted EBITDA lower than Q2, though it expects results will still exceed Q1's €90 million, supported by continued strength in Brazil.
For the full year, the company signaled no major changes to the consensus EBITDA estimate of €508 million. That is a confirmation of the status quo, not an upgrade — precisely what a stock trading at a premium needs to justify its price.
• Debt Is Shrinking, but Valuation Looks Stretched — Net debt fell to €993 million , and the company generated positive free cash flow of €106 million, helped by €55 million in working capital inflows. But at 7.2× forward EV/EBITDA, the stock sits well above its 10-year average of 5.7×. That premium implies investors expect a sharper earnings recovery than management just endorsed.
• Cost Savings Won't Move Fast Enough — Aperam's internal efficiency program delivered €38 million in savings during H1, tracking toward a €150 million target over 2026–28. Progress is on track, but those gains arrive gradually — not fast enough to offset a seasonal Q3 dip and persistently weak European demand that management has now flagged for three straight quarters.
The bottom line: Aperam is recovering, but today's sell-off suggests the market had already paid for the comeback and wanted proof of acceleration — not just seasonal rebound.